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ABSTRAK
Latar belakang: ekstrak biji Nigella sativa (NS) pada penelitian in vivo menunjukkan potensi sebagai anti 
hipertensi karena memiliki efek diuretik, meningkatkan produksi Oksida Nitrit dan menghambat overaktivitas 
sistem saraf simpatis, sehingga potensial digunakan sebagai obat anti hipertensi pada pasien usia lanjut. 
Penelitian ini bertujuan untuk mengetahui pengaruh pemberian ekstrak biji NS pada perubahan tekanan darah 
sistolik (TDS) dan tekanan darah diastolik (TDD) pasien usia lanjut dengan hipertensi. Metode: dilakukan uji 
klinis acak tersamar ganda mulai Juni hingga September 2011 terhadap 76 pasien usia lanjut dengan hipertensi 
di tiga poliklinik di RS Cipto Mangunkusumo Jakarta Indonesia. Dengan alokasi tersamar, subyek dibagi menjadi 
kelompok yang mendapat kapsul berisi ekstrak biji NS 300 mg sebanyak 2 kali sehari selama 28 hari dan kelompok 
yang mendapat plasebo. Tekanan darah (TD) diukur pada hari ke-1 dan ke-28. Dilakukan analisis dengan uji-t 
tidak berpasangan untuk melihat perbedaan tekanan darah pada kedua kelompok setelah intervensi dengan 
prinsip analisis intention to treat. Hasil: dari 85 subjek yang memenuhi kriteria awal, didapatkan 76 subjek 
yang sesuai kriteria penelitian dan dirandomisasi menjadi dua kelompok, masing-masing terdiri dari 38 subjek. 
Pada akhir pengamatan, TDS kelompok NS turun dari 160,4 (SD 15,7) menjadi 145,8 (SD 19,8) mmHg and pada 
plasebo turun dari 160,9 (SD 16,3) menjadi 147,53 (SD 22,0) mmHg (p=0,36). TDD pada kelompok NS turun 
dari 78,3 (SD 11,9) menjadi 74,4 (SD 8,2) dan pada kelompok plasebo turun dari 79,0 (SD 12,4) menjadi 78,2 
(SD 8,9) mmHg. Efek simpang yang dilaporkan adalah dispepsia pada 6 subjek (15,7%), mual pada 3 subjek 
(7,8%) dan konstipasi pada 2 subjek (5,2%). Tidak didapatkan gangguan elektrolit, gangguan fungsi ginjal, 
hati, maupun hipotensi ortostatik. Kesimpulan: meskipun menunjukkan kecenderungan penurunan tekanan 
darah, Nigella sativa belum terbukti dapat menurunkan tekanan darah pasien usia lanjut dengan hipertensi.
Kata kunci: Nigella sativa, hipertensi, usia lanjut.
ABSTRACT
Background: Nigella sativa (NS) seed extract shows diuretic activity, inhibits sympathetic nervous system 
overactivity and increases the production of Nitric Oxide in in vivo studies, thus it has a potential use as an 
adjuvant antihypertensive for elderly population. This study aimed to determine the effect of Nigella sativa seed 
extract to systolic blood pressure (SBP) and diastolic blood pressure (DBP) of elderly patients with hypertension. 
Methods: a double-blind, randomized controlled trial was conducted on elderly subjects with hypertension in 
three outpatient clinics in Cipto Mangunkusumo National Hospital Jakarta Indonesia from June to September 
2011. Subjects were divided into intervention group given 300 mg Nigella sativa seed extract twice daily for 28 
days and into another group which was given placebo. Blood pressure were measured on day 1 and 28. Intention 
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to treat analysis using unpaired t-test to compare blood pressure after intervention between the two groups was 
performed. Results: of a total of 85 patients, 76 subjects fulfilled the study criteria and were randomized into 2 
groups, with 38 subjects in each group. Both groups were comparable in all important prognostic factors. The 
mean systolic blood pressure of the NS group was decreased from 160.4 (SD 15.7) mmHg to 145.8 (SD 19.8) 
mmHg, and from 160.9 (16.3) mmHg to 147.53 (SD 22.0) mmHg in the placebo group (p=0.36). The mean 
diastolic blood pressure in the NS group was decreased from 78.3 (SD 11.9) to 74.4 (SD 8.2) mmHg, and from 
79.0 (SD 12.4) to 78.2 (SD 8.9) in the placebo group (p=0.35). Reported adverse events include dyspepsia in 6 
subjects (15.7%), nausea in 3 subjects (7.8%), and constipation in 2 subjects (5.2%). No electrolyte abnormalities, 
liver and renal toxicities, or orthostatic hypotension were observed. Conclusion: although a trend towards a 
slight decrease in blood pressure was observed, Nigella sativa has not been proven to be effective in reducing 
blood pressure in elderly patients with hypertension.
Keywords: Nigella sativa, hypertension, elderly.
INTRODUCTION
To date, hypertension remains a major health 
problem in various countries. The financial 
burden, both direct and indirect, caused by 
hypertension is substantial. With cardiovascular 
complications that often follows, hypertension 
remains the number one cause of death in the 
elderly.1,2 Results from Riset Kesehatan Dasar 
(Indonesian Basic Health Research) reporting 
that the prevalence of hypertension in Indonesia 
is 63.5% in populations aged 65-74 years old and 
67.2% for those aged 75 years or more.3 Despite 
this high prevalence, control of hypertension 
remains very poor in this population.4 With the 
increase of elderly population in Indonesia which 
is predicted to reach 414% within 35 years, this 
problem becomes more important.5
The importance in decreasing blood pressure 
in elderly patients has been proven by a meta-
analysis on seven large scale clinical trials 
involving a total of 1,670 patients. The analysis 
concluded that a decrease in blood pressure in 
patients aged over 60 years will reduce mortality 
and cardiovascular events significantly within the 
next 4.5 years.6 Reducing 10 mmHg of systolic 
blood pressure or 5 mmHg of diastolic blood 
pressure at the age of 65 means reducing the risk 
of myocardial infarction by 25%, reducing the 
risk of stroke by 40%, and reducing the risk of 
congestive heart failure by 50%.7
Nigella sativa, which is known in Indonesian 
as jinten hitam (black cumin) or habatussauda, 
is a dicotyledon from the family Ranunculaceae 
which has been used to resolve various diseases 
since hundreds of years ago.8 Experimental 
studies on animal models have proven that the 
biological effects of Nigella sativa including 
its effect in diuresis, decreasing sympathetic 
activities, and improving lipid profile, are 
potentially beneficial for the treatment of 
hypertension.9-11 In relation to the rigidity of 
arteries, which is a pathogenesis characteristic of 
hypertension in the elderly, Nigella sativa also 
increases the production of nitrite oxide which 
may inhibit the rigidity of arteries.11
Previous clinical trials by Dehkordi12 
and Qidwai13 involving adult patients with 
hypertension were unable to show conclusive 
results. To our knowledge, no clinical trial has 
been able to prove the efficacy of Nigella sativa 
in elderly with hypertension, therefore we wished 
to perform a clinical trial to prove its efficacy 
in decreasing blood pressure in this specific 
population.
METHODS
This study was a double-blind, controlled, 
randomized clinical trial aimed to investigate 
the role of Nigella sativa in decreasing the blood 
pressure of elderly patients with hypertension. 
This study was conducted in June – September 
2011 at the Geriatric Outpatient Clinic, Renal-
Hypertension Outpatient Clinic, and Internal 
Medicine Outpatient Clinic of the Faculty of 
Medicine of the University of Indonesia/Cipto 
Mangunkusumo National Hospital. The inclusion 
criteria were patients aged ≥60 years with 
hypertension (SBP>140 mmHg and or DBP>90 
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mmHg). The exclusion criteria were patients with 
decreased renal function (Glomerular Filtration 
Rate <30 ml/m3), decreased liver function 
(increased SGPT over 2 times the upper normal 
limit), severe dementia, depression, orthostatic 
hypertension, malignant hypertension, having 
consumed more than three antihypertensive 
agents at maximum dose and refusing to 
participate in the study.
In order to calculate the minimum sample 
size required to acquire a difference in mean 
blood pressure after the intervention between 
the intervention and control groups, the sample 
size formula for independent numerical data was 
used, with standard deviation data taken from 
Qidwai’s study.13 Differences deemed significant 
were 10 mmHg for SBP (systolic blood pressure) 
and 5 mmHg for DBP (diastolic blood pressure), 
with a=0.05 and power 80%. The minimum 
sample size required was 64 subjects.
Subjects were randomized into two groups, 
in which one group received Nigella sativa 
and another group received placebo at the 
time of visit. Allocation concealment was also 
performed. Each patient received 2 capsules per 
day for 28 days. Patients in the treatment group 
received capsules containing a dose of 300 mg 
Nigella sativa extracts, whereas patients in the 
placebo group received capsules of similar color, 
weight, and smell containing flour. Both the 
investigator and study subjects had no knowledge 
of the randomized allocation (i.e. double-blind).
Pat ients  were al lowed to consume 
antihypertensive medications previously taken. 
Lifestyle, dietary habits (including salt, fat, and 
vegetable intake), smoking habits, exercising 
habits, and other supplementation usage were 
continued normally. In order to ensure that the 
drugs were taken by the patients, they were 
packaged in plastic which needed to be torn 
before consumption and was counted during 
examination on the 28th day. Furthermore, a 
family member or caregiver would be asked to 
ensure that the drugs were consumed properly 
and to mark a tick on the drug consumption form. 
Prior to drug administration, patients underwent 
interview, physical examination (including body 
mass index and blood pressure) and laboratory 
examination. Blood pressure measurement 
was performed using validated BP monitor 
(Omron, Kyoto Japan). On day 28, the patient 
would revisit the clinic for another round of 
interview, physical examination, and laboratory 
examination. Patients were deemed to have 
completed the study if they were present at the 
examination on day 28 and have consumed all 
of the drugs with the assigned dose. 
Characteristics (especially characteristics 
which may potentially affect the decrease in 
blood pressure such as age, drugs consumed 
and duration of hypertension) in each of the 
Nigella sativa and placebo group were presented 
as means with standard deviation for numerical 
variables or as a proportion if the variables 
were categorical. A difference in blood pressure 
between the Nigella sativa and placebo group 
after the intervention were analyzed with 
unpaired t-test or its alternatives. All analysis 
would apply a significance level of 5%, in 
conjunction with its 95% confidence interval. 
Analysis at the end of the study were performed 
under the intention to treat analysis principles.
This study was performed conforming to the 
Helsinki declaration, Guideline for Good Clinical 
Practice from ICH Tripartite and consistent with 
the rules of clinical trials in Indonesia. Written 
consent had been obtained from each subject and 
the protocol of this study had approved by local 
independent ethical committee, numbered 283/
PT02.FK/ETIK/2011.
RESULTS
Between July and September 2011, 76 
hypertension patients fulfilled the study subject 
selection criteria. The patients then received 
drugs according to codes listed on a previously 
determined randomization table. At the start of 
the study, there were 38 subjects who were given 
Nigella sativa and the remaining 38 subjects were 
given placebo. As many as 7 subjects (9.2%), 
which consisted of 5 subjects receiving Nigella 
sativa and 2 subjects receiving placebo did not 
complete the study due to nausea (4 subjects; 
5.2%), emergency surgery for abdominal trauma 
(1 subject; 1%), and forgetfulness (2 subjects; 
2.6%). A total of 69 patients completed of the 
study, consisting of 33 subjects in the Nigella 
sativa group and 36 subjects in the control group 
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as presented in Figure 1. Patients who completed 
the study declared that they have consumed 
all the drugs on the previously assigned dose. 
Gastrointestinal disorders in the form of 
nausea and gastric discomfort were reported 
in six subjects receiving Nigella sativa, one of 
whom experienced vomiting without signs of 
dehydration, and two others reported difficulty 
in defecation.
As  presented  in  Table  1 ,  subjec t 
characteristics were comparable across all 
considered prognostic factors. At the end of the 
study, a repeat blood pressure measurement was 
performed and a tendency towards a reduced SBP 
was observed. This was clinically important but 
not statistically significant (p=0.36), as presented 
in Table 2. No significant decrease in DBP 
(p=0.35) was observed in the group receiving 
Nigella sativa, as presented in Table 3.
DISCUSSION
Subject characteristics in this study differs 
relatively from that of a study by Kamso, et al.14 
involving 565 elderly patients with hypertension, 
who were randomly selected from patients of a 
Public Health Centers in Special Capital Region 
of Jakarta, Indonesia. Although most of the 
subjects were females, similar to that of Kamso’s 
study, the mean age in this study was significantly 
higher (72 years old in the intervention group and 
73.8 years old in the control group compared to 
65.9 years old in Kamso’s study). Mean SBP 
in this study was also much higher which was 
160.4 mmHg in the intervention group and 160.9 
mmHg in the control group compared to 141 
mmHg in the Kamso study.
To date, only two studies were known to have 
investigated the effects of Nigella sativa on blood 
pressure, the studies of Dehkordi and Qidwai, 
both observed the young adult population.12,13 
ENROLLMENT Fulfilled inclusion criteria
(n=85)
- Fulfilled exclusion
criteria (n=7)
- Refused to participate
in study (n=2)
Randomization
(n=76)
Allocated to receive intervention (n=38)
- Receive intervention as allocated
(n=38)
Allocated to receive placebo (n=38)
- Receive placebo as allocated
(n=38)
Loss to follow up (n=0)
Stopped intervention (n=5) due to:
-Nausea (n=3)
-Trauma emergency surgery (n=1)
-Forgetfulness (n=1)
Loss to follow up (n=0)
Stopped intervention (n=2) due to:
- Nausea (n=1)
- Forgetfulness (n=1)
Included in analyses (n=38) Included in analyses (n=38)
ALLOCATION
FOLLOW UP
ANALYSIS
Figure 1. Study flowchart
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Table 1. Baseline study subjects characteristics
Variables Nigella sativa (n=38) Placebo (n=38)
Male, % 13 (34) 8 (21)
Age (years), mean (SD) 72 (5.9) 73.8(6.8)
Education ≤ middle school, % 8 (21) 10 (26)
Duration of HT <5 years, % 21 (55) 22 (57.9)
BMI (kg/m2), mean (SD) 24.5(3.5) 24.2(5.2)
SBP (mmHg), mean (SD) 159.4 (15.7) 160 (16,3)
DBP (mmHg), mean (SD) 78.7 (10.9) 79.2 (12.8)
Isolated Systolic Hypertension, % 23 (60) 25 (65)
Grade 1 HT, % 8 (21) 9 (24)
>2 types antihypertensive agents, % 6 (15.7) 8 (21)
Routine consumption of antihypertensive agents 33 (86.8) 32 (84.2)
Type of antihypertensive agent
 - ACE inhibitor, % 10 (26) 8 (21)
 - Angiotensin receptor blocker, % 8 (21) 6 (15.7)
 - Calcium channel blocker, % 5 (13.1) 4 (10.5)
 - Diuretics, % 0 (0) 1 (2)
 - Combination of ACE inhibitor and calcium channel blocker, % 7 (18.4) 9 (24)
 - Combination of angiotensin receptor blocker and calcium 
channel blocker, % 
2 (5.2) 1 (2)
 - Combination of ACE inhibitor, calcium channel blocker, and 
beta blocker, %
4 (10.5) 5 (13.1)
 - Combination of ACE inhibitor, calcium channel blocker, and 
alpha blocker, %
2 (5.2) 3 (7.9)
> 6 total drugs consumed, % 8 (21) 7 (18.4)
Routine NSAID use, % 2 (5.2) 3 (7.9)
Routine steroid use, % 0 (0) 0 (0)
Alcohol consumption >1 glass a day, % 0 (0) 0 (0)
Salt consumption >1 tsp./day, % 10 (26) 13 (34.2)
Smoking >10 cigarettes a day 1 (2) 1 (2)
Routine exercise <2x a week @ 30 minutes, % 25 (65) 23 (63)
Coffee consumption >2 cups a day, % 0 (0) 0 (0)
Diabetes Mellitus, % 13 (34.2) 14 (36.8)
Dyslipidemia, % 2 (5) 1 (2.6)
Albumin (mg/dL), mean (SD) 4.2 (0.37) 4.1 (0.39)
Creatinine (mg/dL), mean (SD) 0.85 (0.17) 0.91 (0.17)
SGPT (mg/dL), mean (SD) 19.5 (6.4) 21.22 (8.3)
Proteinuria more than +1, % 4 (10.5) 6 (15.7)
Table 2. Effects of Nigella sativa to systolic blood pressure
Before 
treatment
mmHg (SB)
After 
treatment
mmHg (SB)
Delta 
(mmHg)
Nigella 
sativa (n=33) 160.4 (15.7) 145.8 (19.8) 14.6
Placebo 
(n=36)
160.9 (16.3) 147.53 (22.0) 13.3
P=0.36*
* unpaired t-test
Table 3. Effects of Nigella sativa to dyastolic blood pressure
Before 
treatment
mmHg (SB)
After 
treatment
mmHg (SB)
Delta 
(mmHg)
Nigella 
sativa (n=33) 78.3 (11.9) 74.4 (8.2) 3.9
Placebo 
(n=36)
79.0 (12.4) 78.2 (8.9) 0.8
P=0.35*
* unpaired t-test
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Qidwai’s study observed blood pressure as a 
secondary outcome with the primary outcome 
being lipid profile.13
There were two important points found 
in this study. Firstly, the administration of 
Nigella sativa seed extract with a dose of 300 
mg twice a day for 28 days in elderly patients 
with hypertension could not significantly reduce 
SBP and DBP. A study by Dehkordi12 tested the 
effects of Nigella sativa on mild hypertension 
in young adult subjects produced statistically 
significant decrease in blood pressure with 2 
mmHg decrease in SBP after a 2x200 mg dose 
regimen for 4 weeks. The Qidwai study used a 
2x500 mg dose for 6 weeks and displayed higher 
SBP reduction (5.16 mmHg), although it has poor 
internal validity with a high dropout percentage, 
reaching 42%, due to low compliance.13 The 
findings of the current study differ from the 
other two studies performed in a young adult 
population. The lack of therapeutic effects 
from Nigella sativa in this study compared to 
placebo appears to be unrelated to the dosage 
or duration, considering that the blood pressure 
was clinically reduced. One explanation for this 
is the rigidity of arteries, which is an important 
part of the pathogenesis of hypertension in the 
elderly, impedes the activity of Nigella sativa 
in reducing blood pressure. Although Nigella 
sativa was found to improve hypertension 
through inhibition on alpha adrenoceptors after 
sympathetic stimuli, increasing the production 
of nitrite oxide, anti-inflammatory activities, 
and anti-sclerotic effects in in vivo studies 
performed on animals, it appears that those 
various mechanisms weren’t able to improve the 
rigidity of arteries in the elderly.
Another possible explanation is that sex 
characteristic of study subjects, which was 
dominated by females, plays a role in impeding 
the effect of Nigella sativa in reducing blood 
pressure. Blood pressure in elderly women has 
been known to be harder to control compared to 
elderly men.15 Data from NHANES noted that 
the difficulty of controlling blood pressure in 
female patients stems from the higher prevalence 
of other cardiovascular risk factors in women, 
such as central obesity, increased total cholesterol 
level, and low LDL (low density lipoprotein) 
level.16
This study also found that Nigella sativa 
had no influence on diastolic blood pressure. 
As previously noted, most subjects suffer from 
Isolated Systolic Hypertension, a condition 
where the systolic blood pressure is high with 
normal or low diastolic blood pressure. The 
rigidity of arteries present in the elderly is a good 
explanation of that concept, while normal or even 
low DBP may be caused by the inability of the 
aorta or other arteries to enlarge during systole 
and contract during diastole, making it hard for 
DBP to increase.
Although gastrointestinal adverse events 
were not severe and most were resolved with 
the administration of proton pump inhibitors 
and increased intake of fiber consumption, 
they were quite bothersome for elderly patients 
considering their physiologically decreased 
meal intake compared to younger patients. 
These gastrointestinal disorders may potentially 
decrease fluid intake even further which will 
increase the risk of dehydration.
Gastrointestinal disorders were not reported 
in the Dehkordi12 and Qidwai13 studies on 
young adult patients. The difference in subject 
characteristics may explain the occurrence of said 
gastrointestinal adverse events. Elderly patients 
also often consume other medications which 
may cause dyspepsia, such as NSAIDs, steroids, 
or anti-platelet related to their comorbidities. 
Comorbidities such as diabetic gastroparesis, 
worsens the symptoms of patients with previous 
history of dyspepsia due to medication. Although 
packaged in capsules, interactions between this 
medication and Nigella sativa in the stomach 
with delayed emptying movements may have 
triggered dyspepsia. No side effects on the liver 
and kidney were found, similar to findings of the 
Dehkordi and Qidwai studies.12,13
The advantages of this study lies in its 
design (randomized, double-blind clinical trial), 
which is the best for experimental studies, and 
in it being the first clinical trial investigating the 
effects of Nigella sativa in the elderly. This study 
is also the first one to confirm that Nigella sativa 
has no therapeutic effects in elderly patients with 
hypertension.
The limitations of this study lies in the fact 
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that the blood pressure measurements were only 
performed at the start and the end of intervention 
without any measurements taken between the 
two points in time. As a result, blood pressure 
fluctuations were not evaluated. Another 
limitation is the relatively short duration of study.
CONCLUSION
Despite showing a clinically significant 
decrease in systolic blood pressure, Nigella sativa 
has not been proven to improve hypertension in 
the elderly. Nigella sativa also has not been 
proven to reduce diastolic blood pressure in 
elderly patients.
REFERENCES
1. Bayley K, Grossardt B, Graves J. Novel use of Kaplan 
Meier methods to explain age and gender differences in 
hypertension control rates. Hypertension. 2008;51:841-
47.
2. Centers for Disease Control and Prevention. Racial/
ethnic disparities in prevalence, treatment, and control 
of hypertension in the United States, 1999-2002. 
MMWR Morb Mortal Wkly Rep. 2007;54:7-9.
3. Departemen Kesehatan Nasional. Riset Kesehatan 
Dasar 2007 [internet]. Jakarta: Badan Penelitian 
dan Pengembangan Kesehatan Departemen 
Kesehatan; 2008 [cited on May 10th 2011]. 
Downloaded from  http://kgm.bappenas.go.id/index.
php?hal=13&keyIdHead=10.
4. Gunawan D, Setiati S. Proporsi hipertensi pada 
usia lanjut dan faktor-faktor yang mempengaruhi 
keterkontrolannya [Thesis]. Jakarta: Universitas 
Indonesia: 2010.
5. Soejono CH. Pengkajian paripurna pada pasien geriatri. 
In: Sudoyo AW, Setyohadi B, Alwi I, Kolopaking MS, 
Setiati S, editors. Buku ajar ilmu penyakit dalam. 4th 
ed. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam; 
2006. p.1425.
6. Musini VM, Tejani AM, Bassett K, Wright JM. 
Pharmacotherapy for hypertension in the elderly. 
Cochrane Database Syst Rev. 2009;4:CD000028.
7. Chobanian A, Bakris G, Black H, Cushman W, Green 
L. Seventh report of the Joint National Committee on 
Prevention, Detection, Evaluation and Treament of 
High Blood Pressure. Hypertension. 2003;42:1206-52.
8. Salem ML. Immunomodulatory and therapeutic 
properties of the Nigella sativa L. seed. Int. J. 
Immunopharmacol. 2005; 5:1749–70.
9. Nader MA, el Agami DS, Suddek GM. Protective 
effects of propolis and thymoquinone on development 
of atherosclerosis in cholesterol-fed rabbits. Arch 
Pharm Res. 2010;337:637-43.
10. ElTahir K, Ashour MM, al-harbi MM. The 
cardiovascular actions of the volatile oil of the black seed 
(Nigella sativa) in rats: elucidation of the mechanism 
of action. Gen Pharmacol. 1993;24(5):1123-31.
11. Ubru U, Burak U, Yusuf S, Reyhan B, Arif K, Faruk 
TH. Cardioprotective effects of Nigella sativa oil on 
cyclosporine A-induced cardiotoxicity in rats. Basic 
Clin Pharmacol Toxicol. 2008;103(6):574-80.
12. Dehkordi F, Kamkhah A. Antihypertensive effect 
of Nigella sativa seed extract in patients with mild 
hypertension. Fundamental and Clin Pharmacol. 
2008;22:447-52.
13. Qidwai W, Hamza H, Qureshi R, Gilani A. Effectiveness, 
safety, and tolerability of powdered Nigella sativa 
(Kalonji) seed in capsules on serum lipid levels, blood 
sugar, blood pressure, and body weight in adults: 
Results of a randomized, double-blind controlled trial. 
J Altern Compl Med. 2009;15:639-44.
14. Kamso S, Rumawas J, Lukito W, Purwantyastuti. 
Determinants of blood pressure among Indonesian 
elderly individuals who are of normal and overweight: 
a cross sectional study in an urban population. Asia Pac 
J Clin Nutr. 2007;16(3):546-53.
15. Lloyd Jones DM, Evans JC, Levy D. Hypertension in 
adults across the age spectrum: current outcomes and 
control in the community. JAMA. 2005;294:466-72.
16. Ong KL, Tso AW, Lam KS, et al. Gender difference 
in blood pressure control and cardiovascular risk 
factors in Americans with diagnosed hypertension. 
Hypertension. 2008;51:1142-8.
